期刊
CURRENT ONCOLOGY REPORTS
卷 14, 期 2, 页码 120-128出版社
SPRINGER
DOI: 10.1007/s11912-012-0215-2
关键词
Survivin; BIRC5; Apoptosis; Cell cycle; Cancer; Solid tumours; Antisense oligonucleotide
类别
资金
- Cancer Research UK
- Lilly UK
- National Institute for Health Research [CL-2010-13-007] Funding Source: researchfish
Survivin is a 16.5 kDa protein that functions to inhibit apoptosis, promote proliferation, and enhance invasion. Absent in most adult tissues, survivin is selectively upregulated in many human tumors, where its overexpression correlates with poor outcome and treatment resistance. Consequently, survivin is a promising target for cancer therapy. Preclinical data demonstrate that survivin inhibition reduces cell proliferation, increases apoptosis, and sensitises cells to cytotoxic agents and radiotherapy. The pharmacological survivin inhibitors LY2181308 and YM155 have demonstrated acceptable toxicity and evidence of therapeutic efficacy as single agents in early-phase clinical trials. Current efforts seek to define the optimum use of survivin inhibitors in combination with cytotoxic therapies, where it is hoped that preclinical evidence of treatment synergy will translate into improved therapeutic efficacy. Results from these ongoing studies are keenly awaited.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据